Haemostasis with cryoprecipitate in patients undergoing surgery for severe von Willebrand disease.
BACKGROUND
There are limited data on the management of haemostasis in patients with severe von Willebrand disease undergoing major surgery. Data on the use of cryoprecipitate in this setting are even more limited. In many developing countries cryoprecipitate is often the only available source of factor replacement. The minimum factor levels required for maintaining haemostasis after surgery have never been carefully evaluated.


METHODS
Data from 3 patients with severe von Willebrand disease who underwent 4 major surgical procedures at our institution, using lower than standard recommended doses of cryoprecipitate were analysed for adequacy of factor replacement and complications.


RESULTS
The average preoperative cryoprecipitate infusion was 22.5 i.u. of factor VIII/kg (range: 15-25). The bleeding time done by the modified Ivy method, 30 minutes after infusion, was normal in all these patients. The average cryoprecipitate support for days 1-3 was 16.5 i.u. of factor VIII/kg/day (range: 12.5-25) and for days 4-10 was 12.4 i.u. of factor VIII/kg/day (range: 8.3-16). The mean duration of factor replacement was 12 days (range: 7-17). Two patients had delayed bleeding, one on day 3 attributed to the inadvertent use of a non-steroidal anti-inflammatory drug and the second on day 10 which was probably secondary to septicaemia. Bleeding resolved in both these patients as soon as the precipitating factors were relieved.


CONCLUSIONS
The total amount of factor replaced in our patients is approximately half of what would have been used if the usual recommendations were followed. The data suggests that lower doses of cryoprecipitate could be adequate for major surgery and wound healing in severe von Willebrand disease. This will lead to lowering of costs and reducing the risk of transfusion-associated virus infection.
Mathews
V
V
Christian Medical College and Hospital, Vellore, Tamil Nadu, India.
Srivastava
A
A
Nair
S C
SC
Chandy
M
M
D000328:Adult; D017046:Cost Savings; D005169:Factor VIII / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D005340:Fibrinogen / Q000008:administration & dosage* / Q000627:therapeutic use; D006488:Hemostasis, Surgical; D006801:Humans; D008297:Male; D011182:Postoperative Care; D014842:von Willebrand Diseases / Q000601:surgery*
C026912:cryoprecipitate coagulum; D005169:Factor VIII; D005340:Fibrinogen